A Phase 3 interventional study of Lurasidone and Placebo in Bipolar Depression, sponsored by Sumitomo Pharma America, Inc.. Completed at 75 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-11-26.
Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing lurasidone in Bipolar Disorder — 2 open to participants now, 2 under way, none of them phase 3. lurasidone · Bipolar Disorder.
Among the 17 studies testing lurasidone in Bipolar Disorder, this one is the 7th largest by enrollment, is the only one that started in 2010, is one of 11 in phase 3, and was the 4th registered.
1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →2 of the 17 studies testing lurasidone in Bipolar Disorder are open now, in 2 countries. Recruiting first, the newest first:
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 16–65 · Healthy volunteers
Martin Lan · Sites in United States
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 356 is above the median of 64 across 1,280 interventional studies indexed under Bipolar Disorder.
Median enrollment 348 across the 17 interventional studies. Of the 14 that completed or were terminated, 12 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 17 have an industry lead sponsor. The 9 most frequent:
This study is registered under Sumitomo Pharma America, Inc., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sumitomo Pharma America, Inc. is the lead sponsor of 181 studies on the registry; 5 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 21 (64%) have results posted.
Sumitomo Pharma Co., Ltd. has 9 studies filed under Bipolar Disorder — fewer than ten, so there is no comparison to draw.
1 of the studies testing lurasidone in Bipolar Disorder that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05480150First Affiliated Hospital of Zhejiang UniversityChinese Longitudinal and Systematic Study of Bioplar Disorder | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing lurasidone in Bipolar Disorder, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Lurasidone HCI is a compound that is a candidate for the treatment of bipolar I depression. This clinical study is designed to test the hypothesis that Lurasidone in combination with either Lithium or Divalproex is effective among patients with bipolar I depression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Lurasidone
Drug: Placebo
Tablets 20-120 mg, PM dosing,daily for 6 weeks
Also known as: Latuda
Equivalent to Lurasidone dosing
Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6)
MADRS total score ranges from a minimum of 0 to a maximum of 60. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.
Time frame: Baseline to week 6
Mean Change From Baseline to Endpoint (Week 6) in: Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)
CGI-EP-S depression score ranges from a minimum of 0 to a maximum of 7. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.
Time frame: Baseline to week 6
Mean Change From Baseline to Endpoint (Week 6) in: Sheehan Disability Scale (SDS) Total Score
SDS total score ranges from a minimum of 0 to a maximum of 30. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.
Time frame: Baseline to week 6
| Milestone | Lurasidone 20-120 mg Flexible Dose+Li/VPA | Placebo + Li/VPA |
|---|---|---|
| Started | 180 | 176 |
| Completed | 148 | 140 |
| Not completed | 32 | 36 |
MADRS total score ranges from a minimum of 0 to a maximum of 60. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.
| units on a scale | Lurasidone 20-120 mg Flexible Dose+Li/VPA | Placebo + Li/VPA |
|---|---|---|
| Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6) | -11.8 ± 0.76 | -10.4 ± 0.79 |
CGI-EP-S depression score ranges from a minimum of 0 to a maximum of 7. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.
| units on a scale | Lurasidone 20-120 mg Flexible Dose+Li/VPA | Placebo + Li/VPA |
|---|---|---|
| Mean Change From Baseline to Endpoint (Week 6) in: Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression) | -1.36 ± 0.099 | -1.13 ± 0.102 |
SDS total score ranges from a minimum of 0 to a maximum of 30. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.
| units on a scale | Lurasidone 20-120 mg Flexible Dose+Li/VPA | Placebo + Li/VPA |
|---|---|---|
| Mean Change From Baseline to Endpoint (Week 6) in: Sheehan Disability Scale (SDS) Total Score | -5.4 ± 0.85 | -5.4 ± 0.74 |
Collected over 13 December 2010 to 7 August 2012. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lurasidone 20-120 mg Flexible Dose+Li/VPA | — | 5/177 (2.8%) | 79/177 (44.6%) |
| Placebo + Li/VPA | — | 3/171 (1.8%) | 63/171 (36.8%) |
| Event | Lurasidone 20-120 mg Flexible Dose+Li/VPA | Placebo + Li/VPA |
|---|---|---|
| ManiaPsychiatric disorders | 0/177 | 1/171 |
| Transient Ischemic AttackNervous system disorders | 0/177 | 1/171 |
| Flank PainMusculoskeletal and connective tissue disorders | 0/177 | 1/171 |
| DepressionPsychiatric disorders | 1/177 | 0/171 |
| Suicidal IdeationPsychiatric disorders | 1/177 | 0/171 |
| Intentional OverdoseInjury, poisoning and procedural complications | 1/177 | 0/171 |
| Anaphylactic ShockImmune system disorders | 1/177 | 0/171 |
| Disease ProgressionGeneral disorders | 1/177 | 0/171 |
| Depression SuicidalPsychiatric disorders | 1/177 | 0/171 |
| AngioedemaSkin and subcutaneous tissue disorders | 1/177 | 0/171 |
| Event | Lurasidone 20-120 mg Flexible Dose+Li/VPA | Placebo + Li/VPA |
|---|---|---|
| AkathisiaNervous system disorders | 25/177 | 9/171 |
| InsomniaPsychiatric disorders | 15/177 | 18/171 |
| NauseaGastrointestinal disorders | 18/177 | 16/171 |
| HeadacheNervous system disorders | 15/177 | 15/171 |
| SomnolenceNervous system disorders | 15/177 | 5/171 |
| DiarrhoeaGastrointestinal disorders | 14/177 | 10/171 |
| TremorNervous system disorders | 11/177 | 9/171 |
| DizzinessNervous system disorders | 9/177 | 9/171 |
This is the full analysis set (intent-to-treat population)
| Age, Categorical(Participants) | Lurasidone 20-120 mg Flexible Dose+Li/VPA | Placebo + Li/VPA | Total |
|---|---|---|---|
| <=18 years | 3 | 0 | 3 |
| Between 18 and 65 years | 166 | 161 | 327 |
| >=65 years | 7 | 5 | 12 |
| Age Continuous(years) | Lurasidone 20-120 mg Flexible Dose+Li/VPA | Placebo + Li/VPA | Total |
|---|---|---|---|
| Mean | 43.1 ± 11.90 | 44.1 ± 11.99 | 43.6 ± 11.94 |
| Sex: Female, Male(Participants) | Lurasidone 20-120 mg Flexible Dose+Li/VPA | Placebo + Li/VPA | Total |
|---|---|---|---|
| Female | 91 | 93 | 184 |
| Male | 85 | 73 | 158 |
| Region of Enrollment(participants) | Lurasidone 20-120 mg Flexible Dose+Li/VPA | Placebo + Li/VPA | Total |
|---|---|---|---|
| United States | 71 | 63 | 134 |
| Czech Republic | 9 | 8 | 17 |
| Slovakia | 17 | 21 | 38 |
| Canada | 9 | 8 | 17 |
| Ukraine | 17 | 14 | 31 |
| Lithuania | 10 | 9 | 19 |
| Peru | 6 | 7 | 13 |
| Colombia | 12 | 10 | 22 |
| Japan | 5 | 4 | 9 |
| India | 20 | 22 | 42 |
The record gives a start of Nov 2010, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lurasidone
Sumitomo Pharma America, Inc. →